“Cardiorenal Syndrome: New Insights” (Hybrid Event)

Mark Sarnak, MD

Chief, Division of Nephrology; Professor of Medicine

Tufts University School of Medicine

Mark J. Sarnak, MD MS is Chief of the Division of Nephrology at Tufts Medical Center (TMC) and the Gerald J. and Dorothy R. Friedman Professor of Medicine at Tufts University of Medicine (TUSM).

He received his undergraduate degree from Columbia University and his medical degree from the College of Physicians and Surgeons of Columbia University. He completed his residency at the Massachusetts General Hospital in Boston and his nephrology fellowship at TMC.

His primary research interest is cardiovascular disease in Chronic Kidney Disease (CKD). He has also focused on cognitive function, novel biomarkers of kidney disease progression and hypertension. His research has continuously been funded by the NIH since 2000. Currently, he is running four research studies focused on Chronic and Acute Kidney Disease with a particular look at age and Cardiovascular Disease effects when Kidney Disease is present.

He also has a long record of national and international leadership positions. He was Co-Chair of the American Heart Association (AHA) Scientific Statement “CKD as a Risk Factor for Cardiovascular Disease”, Co-Chair of the “KDIGO CAD and Valvular Disease Controversies Conference,” and Chair of an AHA Scientific Statement on the “Cardiovascular Impact of Home Dialysis Therapies in Patients with ESKD.”

He is currently on the Steering Committee for the KDIGO controversies conference on Heart Failure and CKD. Dr. Sarnak is a previous recipient of the Shaul Massry Award from the National Kidney Foundation, the TUSM Distinguished Faculty Award and has been elected to the American Association of Physicians. He is an active clinician and has been recognized in Boston Magazine Best Doctors for 13 of the last 14 years.

Join Meeting!

Objectives

• Appraise the pathophysiology of decreased kidney function in the cardiorenal syndrome.
• Evaluate the difference in prognosis between baseline and change in kidney function with outcomes in the cardiorenal syndrome.
• Assess treatments for the cardiorenal syndrome.

Faculty Disclosures

Dr. Sarnak has indicated the following relevant financial relationships with commercial interests:

• Consultant – Akebia
• Stock or Stock Options – Eli Lilly

Planning Committee Disclosure

Dr. Deshpande has indicated the following relevant financial relationships with commercial interests:

• Advisor – GI Health Foundation

Dr. Weiss has indicated the following relevant financial relationships with commercial interests:

• Advisor – Prizm LLC
  
• Advisor – Fortress Pharmaceuticals

Target Audience

Primary care physicians.

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”